![Emanuele Marra](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Emanuele Marra currently works as a Chief Operating Officer at Takis Srl.
Postes actifs de Emanuele Marra
Sociétés | Poste | Début |
---|---|---|
Takis SRL
![]() Takis SRL BiotechnologyHealth Technology Takis Srl is an Italian biotech company founded in November 2009 by a group of scientists from IRBM, a research center near Rome, Italy. Takis is based in Castel Romano, IT and has more than 10 years of experience in drug discovery, contributing to the validation of new targets for the treatment of chronic viral diseases and cancer, and to a number of IND/CSA filings in the areas of virology and oncology. The private company specializes in drug discovery in oncology and has expertise in vivo electro-gene-transfer, which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis' pipeline includes four cancer vaccine candidates based on this technology. The company was founded by Luigi Aurisicchio, who has been the CEO since incorporation. | Directeur des opérations | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Takis SRL
![]() Takis SRL BiotechnologyHealth Technology Takis Srl is an Italian biotech company founded in November 2009 by a group of scientists from IRBM, a research center near Rome, Italy. Takis is based in Castel Romano, IT and has more than 10 years of experience in drug discovery, contributing to the validation of new targets for the treatment of chronic viral diseases and cancer, and to a number of IND/CSA filings in the areas of virology and oncology. The private company specializes in drug discovery in oncology and has expertise in vivo electro-gene-transfer, which can be used for a variety of clinically useful applications, from vaccine development to somatic gene therapy. Takis' pipeline includes four cancer vaccine candidates based on this technology. The company was founded by Luigi Aurisicchio, who has been the CEO since incorporation. | Health Technology |